FINWIRES · TerminalLIVE
FINWIRES

GSK's Linerixibat Gets UK Nod for Itch Linked to Biliary Disease

By

-- GSK's (GSK) Linerixibat, to be marketed as Lynavoy, has been approved by the UK's Medicines and Healthcare products Regulatory Agency for the treatment of itching in adults with primary biliary cholangitis, the agency said Friday.

The oral therapy aims to reduce bile acid buildup linked to the rare liver disease, which can cause persistent itching, the agency said.

The approval was supported by phase 3 data showing Linerixibat significantly reduced itching and improved sleep disruption compared with placebo, it added.

Shares of GSK were down 1.2% in Friday trading.

Price: $52.01, Change: $-0.30, Percent Change: -0.57%

Related Articles

Australia

Evercore ISI Adjusts Willis Towers Watson Price Target to $360 From $390

Willis Towers Watson Public (WTW) has an average rating of overweight and mean price target of $346.85, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $260.90, Change: $+4.69, Percent Change: +1.83%

$WTW
Research

Eldorado Gold Maintained at Hold at Stifel Canada Following Q1 Results; Price Target Kept at C$65.00

Stifel Canada on Friday maintained its hold rating on the shares of Eldorado Gold (ELD.TO, EGO) and its C$65.00 price target following the miner's first-quarter results."Eldorado reported Q1/26 adjusted EPS of $0.95 vs. our $0.80 (consensus $0.67) and adjusted EBITDA of $336Mln vs our $307Mln on a 1.6% attributable gold production of 100.4Koz (-19% QoQ) vs. our 98.8Koz - in-line with H2-weighted FY26 guidance of 490-590Koz. Q1/26 FCF was -$129.1Mln (-$62.9Mln ex-Skouries) vs. our -$83.4Mln, driven by $135.6Mln of Skouries project capital and $48.5Mln of accelerated operational capital spent. Skouries first concentrate remains on track for Q3/26 with commercial production in Q4/26 and total project capital revised up by $155Mln to $1.315Bln due to labour, project support and overhead, materials and F/X impacts. FY26 consolidated gold production (H2-weighted) and cost guidance was maintained at 490-590Koz (ex-Skouries) at TCC of $1,220-$1,420/oz and AISC of $1,670-$1,870/oz. George Burns will retire as CEO in Q3/26; President Christian Milau will succeed him and join the Board," analyst Ralph Profiti wrote.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $40.01, Change: $-1.96, Percent Change: -4.67%

$EGO$ELD.TO
Australia

BP Said to Explore Exiting UK North Sea Operations, Bloomberg Reports

Price: $46.65, Change: $-0.73, Percent Change: -1.55%

$BP